Sirtuin 1: Endocan and Sestrin 2 in Different Biological Samples in Patients with Asthma. Does Severity Make the Difference?

Background: Sestrin 2, Endocan, and Sirtuin 1 are distinct molecules with some biologic actions associated with asthma pathophysiology. The aim of the present study was to determine the molecular level differences attributable to underlying asthma severity. Methods: We initially recruited 85 asthmatics with a wide spectrum of severity. All of the patients were optimally treated according to current guidelines. Demographics, test results of lung function, and treatment regimes of all patients were recorded. Sestrin 2, Endocan, and Sirtuin 1 were measured in different biological samples (sputum with two processing methods and serum). Results: A total of 60 patients (35 with severe asthma) were analyzed, since 25 patients failed to produce an adequate sample of sputum. Patients with severe asthma showed significantly higher values for Sestrin 2 [pg/mL], measured in both sputum supernatant and cell pellet, compared to those with mild to moderate asthma [9524 (5696, 12,373) vs. 7476 (4265, 9273) p = 0.029, and 23,748 (15,280, 32,742) vs. 10,084 (3349, 21,784), p = 0.008, respectively]. No other significant differences were observed. No significant associations were observed between biomarkers, inflammatory cells, and lung function. Conclusion: Sestrin 2 is increased in patients with severe asthma as part of a mechanism that may modify structural alterations through the imbalance between oxidative stress and antioxidant activity.

[1]  L. Heaney,et al.  Different endotypes and phenotypes drive the heterogeneity in severe asthma , 2020, Allergy.

[2]  Ke Ma,et al.  Sirtuins as novel targets in the pathogenesis of airway inflammation in bronchial asthma. , 2019, European journal of pharmacology.

[3]  Xiaohua Du,et al.  Sestrin2 is involved in asthma: a case–control study , 2019, Allergy, Asthma & Clinical Immunology.

[4]  M. Kechagia,et al.  Serum endocan levels in patients with chronic obstructive pulmonary disease: a potential role in the evaluation of susceptibility to exacerbation , 2018, Clinical Chemistry and Laboratory Medicine.

[5]  G. Canonica,et al.  The Severe Heterogeneous Asthma Research collaboration, Patient-centred (SHARP) ERS Clinical Research Collaboration: a new dawn in asthma research , 2018, European Respiratory Journal.

[6]  Xiongbiao Wang,et al.  Suppression of Sirtuin-1 Increases IL-6 Expression by Activation of the Akt Pathway During Allergic Asthma , 2017, Cellular Physiology and Biochemistry.

[7]  Jianfang Liu,et al.  Recent Insights into the Biological Functions of Sestrins in Health and Disease , 2017, Cellular Physiology and Biochemistry.

[8]  P. Barnes,et al.  Decreased Serum Sirtuin-1 in COPD , 2017, Chest.

[9]  C. Brightling,et al.  Defective sirtuin-1 increases IL-4 expression through acetylation of GATA-3 in patients with severe asthma. , 2016, The Journal of allergy and clinical immunology.

[10]  E. Bleecker,et al.  International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma , 2013, European Respiratory Journal.

[11]  K. C. K. Lloyd,et al.  Sestrin-2, a repressor of PDGFRβ signalling, promotes cigarette-smoke-induced pulmonary emphysema in mice and is upregulated in individuals with COPD , 2013, Disease Models & Mechanisms.

[12]  K. Tobe,et al.  Sirtuin 1 activator SRT1720 suppresses inflammation in an ovalbumin‐induced mouse model of asthma , 2013, Respirology.

[13]  F. Andris,et al.  Sirtuin 1 Promotes Th2 Responses and Airway Allergy by Repressing Peroxisome Proliferator-Activated Receptor-γ Activity in Dendritic Cells , 2011, The Journal of Immunology.

[14]  M. Karin,et al.  Stressin' Sestrins take an aging fight , 2010, EMBO molecular medicine.

[15]  H. von Melchner,et al.  Inactivation of sestrin 2 induces TGF-β signaling and partially rescues pulmonary emphysema in a mouse model of COPD , 2010, Disease Models & Mechanisms.

[16]  H. Chae,et al.  Involvement of sirtuin 1 in airway inflammation and hyperresponsiveness of allergic airway disease. , 2010, The Journal of allergy and clinical immunology.

[17]  J. Yoshikawa,et al.  Role of microvascular permeability on physiologic differences in asthma and eosinophilic bronchitis. , 2004, American journal of respiratory and critical care medicine.

[18]  N. Aoike,et al.  Expression of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin immunoreactivity in asthmatic airways and its relationship to angiogenesis. , 2001, The Journal of allergy and clinical immunology.

[19]  P. Sterk,et al.  Induced sputum in adolescents with severe stable asthma. Safety and the relationship of cell counts and eosinophil cationic protein to clinical severity. , 1999, The European respiratory journal.

[20]  J. Kips,et al.  Methods for sputum induction and analysis of induced sputum: a method for assessing airway inflammation in asthma. , 1998, The European respiratory journal. Supplement.

[21]  J. Tavernier,et al.  ESM-1 Is a Novel Human Endothelial Cell-specific Molecule Expressed in Lung and Regulated by Cytokines* , 1996, The Journal of Biological Chemistry.

[22]  John L. Hankinson,et al.  Standardization of Spirometry, 1994 Update. American Thoracic Society. , 1995, American journal of respiratory and critical care medicine.

[23]  E. Allam,et al.  Relationship between Serum Level of Endocan and Severity of Childhood Asthma. , 2018, Egyptian Journal of Immunology.

[24]  K. Samitas,et al.  T2-low asthma: current approach to diagnosis and therapy , 2017, Current opinion in pulmonary medicine.

[25]  A. Buist.  Standardization of spirometry. , 1987, The American review of respiratory disease.